ライフサイエンスコーパス: malignant pleural mesothelioma

1 nded as a therapy for patients with advanced malignant pleural mesothelioma.

2 VAT-PP and talc pleurodesis in patients with malignant pleural mesothelioma.

3 ) identified 68 with advanced ASS1-deficient malignant pleural mesothelioma.

4 idered the best available serum biomarker of malignant pleural mesothelioma.

5 veral control groups and 1,026 patients with malignant pleural mesothelioma.

6 acy of trimodality therapy in stage I to III malignant pleural mesothelioma.

7 rging therapeutic option in the treatment of malignant pleural mesothelioma.

8 atment with cisplatin alone in patients with malignant pleural mesothelioma.

9 our activity in patients with PD-L1-positive malignant pleural mesothelioma.

10 e extent of disease in patients with diffuse malignant pleural mesothelioma.

11 s promise in the palliation of patients with malignant pleural mesothelioma.

12 ne depletion in patients with ASS1-deficient malignant pleural mesothelioma.

13 Patients with malignant pleural mesothelioma, a rapidly progressing ma

14 Patients with measurable advanced malignant pleural mesothelioma and disease progression a

15 y of trimodality therapy in the treatment of malignant pleural mesothelioma and identify prognostic f

16 val in patients with pleural effusion due to malignant pleural mesothelioma, and talc pleurodesis mig

17 am of the type I IGF receptor in a subset of malignant pleural mesothelioma cell lines and determined

18 d report here on the interim analysis of the malignant pleural mesothelioma cohort.

19 409 patients with malignant pleural mesothelioma, from 76 centres in the U

20 urvival and quality of life in patients with malignant pleural mesothelioma have, to our knowledge, n

21 Malignant pleural mesothelioma incidence continues to ri

22 published literature of clinical studies in malignant pleural mesothelioma, including phase II trial

23 Malignant pleural mesothelioma is a highly aggressive ca

24 Malignant pleural mesothelioma is a relatively uncommon

25 Malignant pleural mesothelioma is almost always fatal, a

26 Malignant pleural mesothelioma is an aggressive malignan

27 Malignant pleural mesothelioma is an aggressive primary

28 ic cell-based immunotherapy in patients with malignant pleural mesothelioma is feasible, well-tolerat

29 The incidence of malignant pleural mesothelioma is increasing throughout

30 ling and dishevelled (Dvl) overexpression in malignant pleural mesothelioma (MM).

31 Malignant pleural mesothelioma (MPM) carries a poor prog

32 gulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compa

33 Malignant pleural mesothelioma (MPM) expresses high leve

34 Malignant pleural mesothelioma (MPM) is a deadly disease

35 Malignant pleural mesothelioma (MPM) is a disease of inc

36 Malignant pleural mesothelioma (MPM) is a highly aggress

37 Malignant pleural mesothelioma (MPM) is a highly aggress

38 Malignant pleural mesothelioma (MPM) is a highly lethal,

39 Malignant pleural mesothelioma (MPM) is a rare malignanc

40 Malignant pleural mesothelioma (MPM) is an aggressive ca

41 Malignant pleural mesothelioma (MPM) is an aggressive ca

42 Malignant pleural mesothelioma (MPM) is an aggressive hu

43 Malignant pleural mesothelioma (MPM) is an aggressive ne

44 Malignant pleural mesothelioma (MPM) is an aggressive th

45 Human malignant pleural mesothelioma (MPM) is considered a rar

46 Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an

47 d pemetrexed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell l

48 = 99) and targeted exomes (n = 103) from 216 malignant pleural mesothelioma (MPM) tumors.

49 Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (On

50 ated receptor-1 (PAR1, F2R) on the growth of malignant pleural mesothelioma (MPM), using human MPM ce

51 plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM).

52 ectomy (EPP) in the treatment of epithelioid malignant pleural mesothelioma (MPM).

53 nd gemcitabine have single-agent activity in malignant pleural mesothelioma (MPM).

54 se (RTK) has not been extensively studied in malignant pleural mesothelioma (MPM).

55 rug combination exclusively in patients with malignant pleural mesothelioma (MPM).

56 ge to undergoing cancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unc

57 The pathological distinction between malignant pleural mesothelioma (MPM)and adenocarcinoma (

58 ich has been shown to be highly expressed in malignant pleural mesotheliomas (MPM), was detected in s

59 6 non-small-cell lung cancer (NSCLC), and 71 malignant pleural mesotheliomas (MPM).

60 NA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present i

61 Malignant pleural mesotheliomas (MPMs) often show CDKN2A

62 ough SV40 oncoproteins have been detected in malignant pleural mesotheliomas (MPMs), their role in th

63 Ten patients with malignant pleural mesothelioma received metronomic cyclo

64 prevent procedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, an

65 Our previous microarray analysis of malignant pleural mesothelioma revealed alterations in c

66 key signaling pathways of the IGF system in malignant pleural mesothelioma specimens.

67 efore, IGF system components represent novel malignant pleural mesothelioma therapeutic targets for i

68 e clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 stud

69 hat multiple mechanisms likely contribute to malignant pleural mesothelioma tumorigenesis.

70 fulness of (18)F-FDG-CI in the assessment of malignant pleural mesothelioma using histopathology as t

71 nty-nine patients with histologically proven malignant pleural mesothelioma were enrolled (26 male pa

72 viously treated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 cen

73 Despite several attempts at treating malignant pleural mesothelioma with various modalities,

74 Our data suggest that in malignant pleural mesothelioma, Wnt signaling is activat